Equillium, Inc. (EQ)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.32
- As of
Kresmion compiles this page from EQ's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Equillium, Inc. (EQ): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-05.
See the full EQ dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for EQ on one page. Preview it with sample data, then open it live with a free account.
Preview the EQ dossierActive signals for EQ
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 28.7%, EPS $-0.04 vs $-0.0561 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 79% of EQ (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +76% to EQ (2026Q2)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 16.1% - EPS $-0.16 vs $-0.1906 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 59.8% - EPS $-0.06 vs $-0.1493 estimate
FREE, NO ACCOUNT
Every signal on EQ, as it fires
You are seeing 5 of 7 signals recorded on EQ since 2026-05-31.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in EQ (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 29446K106 · 2026Q2 | $2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 29446K106 · 2026Q2 | $662K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 29446K106 · 2026Q2 | $319K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 29446K106 · 2026Q2 | $137K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, EQ
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
EQ against its peers
EQ's operating margin of -57.5% ranks in the 75th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-01-31.
| Metric | EQ | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 41.1M USD | 1.4M USD | 95 | 10 |
| Operating margin | -57.5% | -408.4% | 75 | 9 |
| Net margin | -54.5% | -725.2% | 77 | 10 |
| Return on equity | -78.3% | -72.9% | 44 | 16 |
| 1 year | 3.1% | -23.0% | 78 | 19 |
Peers (22): ACRV, CRDF, PMN, ONCY, AARD, CRBP, PTHS, TNYA, KZIA, NTRB, CGTX, NTHI, ICCC, NRXS, OSTX, VRCA, RLYB, MNOV, IMUX, OKUR, GANX, BMEA. Left out: TELO (no annual filing), OKYO (period gap), RTSN (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-01-31. Every figure is one full fiscal year read from one annual filing (EQ: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow EQ on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to EQ for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.